Despite a range of new and unique dosage forms entering the market, capsules are still the preferred format for global consumers, with innovative new capsule technologies giving brands the opportunity to stand out in a crowded marketplace, says Lonza.
Lonza has added to its Capsugel product range by introducing a titanium dioxide-free (TiO2-free) white hard gelatine capsule that meets new TiO2-free needs for foods in the European Union.
Bacthera, the joint venture between Chr. Hansen and Lonza, is to team up with Seres Therapeutics to manufacture Seres’ lead product candidate for recurrent Clostridioides difficile infection (rCDI).
The European Food Safety Authority’s (EFSA) recent decision to class titanium dioxide (TiO2) as an unsafe food additive sets in motion actions to reduce its use in foods like soups, sauces and processed nuts.
Lonza is to sell off two European sites to NextPharma in a deal that gives the contract development and manufacturing firm facilities to work with lipid oral dosage forms for the nutrition and pharma markets.
The shift to online events continues as NutraIngredients' Healthy Ageing Online Conference kicks off next week, in which the team once again delves into the link between nutrition and healthy ageing.
Lonza’s €78.2m ($93m) investment in its Capsules and Health Ingredients (CHI) Division will increase the capsule production capacity by 15%, according to company executives.
Lonza recently announced the launch of its new TWK10 probiotic ingredient, a Lactobacillus plantarum strain that is isolated from fermented Taiwanese Kimchi.
Bacthera, the joint venture between Chr. Hansen and Lonza looking into Live Biotherapeutic Products (LBP), announces Lukas Schüpbach as the company’s new CEO.
Swiss pharmaceutical and nutritional ingredients player Lonza beat 2017 earnings expectations, but forecast a rise in operating profit margin this year that fell short of analysts’ hopes, knocking its shares.
A new partnership between Lonza and phosphatidylserine supplier Lipogen will result in an improved nutritional ingredient and cognitive health portfolio for the company.
Yesterday’s article Carnitine transporter may adapt to lower levels in vegetarians: Study incorrectly stated that Lonza’s L-Carnitine ingredient Carnipure is derived from animal sources. In fact, it is vegetarian.
Swiss ingredients firm Lonza has agreed an exclusive multi-year supply agreement with supplementary nutrition company Multipower for the delivery of Carnipure, a pure cyrstaline L-carnitine.
Swiss ingredients firm Lonza has highlighted a strong performance of its nutritional ingredients, which, it says, reflected a recovering economy and an upturn in consumer markets.
DSM Nutritional Products and Lonza will continue a decades-old working relationship, as the companies seek to “intensify partnerships” as the economic climate bites.
Lonza has extended the reach of its Fiberaid prebiotic into the US
market with the signing of distribution deals with partners the
E.T. Horn Company and Del-val Food Ingredients.
Lonza has lost a patent infringement suit in Germany relating to
its Lonza DHA fatty acid, which was brought against it by US-based
Martek Biosciences Corp.
Lonza is building the technological basis of its nutrition business
with the acquisition of assets from Canada's SAM Electron
Technologies, plus the license for innovative and ecological
vitamin K production technology.
Lonza has reported the integration of its new assets into its
nutrition activities and saw demand increase for its existing store
of healthy ingredients in 2006 - yet margins continued to slide.
Swiss chemicals group Lonza has announced a strategic investment of
$200m in its operations in China, with the investment boosting all
the business including its rapidly expanding nutrition business
portfolio.
Lonza has boosted its capacity to produce peptides through liquid
phase technology with the €120 million acquisition of UCB's
Bioproducts manufacturing division.
Swiss fine chemicals group Lonza said yesterday that it saw strong
demand for its nutrition products during the first half but high
raw material and energy costs continued to erode margins, writes
Dominique Patton.
Swiss chemicals firm Lonza has carried out a new study which
confirms that supplementation with L-Carnitine can significantly
increase fatty acid oxidation in healthy adults in a short period
of time without causing loss of muscle...
Swiss chemicals firm Lonza has opened a new production facility in
the Czech Republic that would allow it to increase output of the
health ingredient L-carnitine, if demand continues to grow.
Directors at Swiss fine chemicals group Lonza have appointed a
former BASF manager as their new chief executive, after major
losses led to the resignation of Markus Gemuend earlier this year.
Swiss chemicals company Lonza this week report on a new study
showing that supplements of its L-Carnitine Crystalline
significantly increases fatty acid oxidation in healthy adults.
Swiss L-carnitine specialist Lonza has signed US-based Metagenics
to market its stomach health supplement PepZin GI to healthcare
professionals in the US and Europe.
Swiss fine chemicals producer Lonza is facing increasing pressure
from emerging markets with sales of its organic and performance
chemicals dropping 11 per cent in this year's first half.
Swiss chemicals firm Lonza is strengthening its position in the
vitamin B3 market, with construction of a new niacinamide plant at
its Guangzhou site in China.
Swiss intermediates and fine chemical company Lonza said today it
is to cut around 500 jobs mainly in Europe and the US as part of a
restructuring programme to reduce the negative effects of the
current economy on most of its business...
Swiss chemicals company the Lonza Group said today it topped the
previous year's performance, with operating income, excluding
non-recurring items, up from CHF413 million to CHF419 million
(€286.5m). The group confirmed its targets...
Swiss chemicals group Lonza has patented a method for increasing
intestinal absorption of fat soluble vitamins in post-menopausal
women, using its L-carnitine product.
Lonza Ltd and Lonza Inc, both subsidiaries of Swiss chemicals
company Lonza Group, have filed a series of patent infringement
lawsuits against supplement companies Carnitech, Barrington,
Stauber and Axel Chemical in the US.
Swiss fine chemicals company Lonza said today that Martin Ebner's
BZ Group Holding plans to sell its 19.8 per cent stake in the
business in the coming weeks in a bid to raise cash for the
investor group.
Lonza, the Swiss-based pharmaceuticals company, has said that the
US Food and Drug Administration has allowed the sale of PepZin GI,
the subject of a new dietary ingredient submission to the federal
agency.
Swiss speciality chemicals group Lonza announced yesterday that it
was to restructure two business sectors, resulting in the loss of
225 jobs or 3 per cent of its 6,400 workforce.
Switzerland's Lonza group has confirmed its commitment to the
construction of a major new production facility in the town of Visp
with the announcement of a SFr100 million (€68.4m) investment in a
biopharmaceuticals manufacturing...
Swiss-based life science chemical company Lonza has set up a cGMP
manufacturing capacity for large scale solid phase manufacture of
peptides at its Visp (CH) facility.
